Skip To Main Content
Edward Cliff on Muck Rack

Edward Cliff

As seen in: Apple Podcasts, The New York Times, Nature, Wiley Online Library, Goats & Soda, NPR, Sydney Morning Herald, JAMA Oncology, The Age, Brisbane Times and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Edward

Contact Edward, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma

|
By Ghulam Rehman Mohyuddin, Edward Cliff, Rajshekhar Chakraborty
| Nature Verified
We appreciate Merz and Gagelmann’s thoughtful response to our Comment on the future of ciltacabtagene autoleucel (cilta-cel) in myeloma (Mohyuddin, G. R., Cliff, E .R. S. & Chakraborty, R. Does ciltacabtagene autoleucel have a future in multiple myeloma? Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-026-01159-6 (2026))1. Our interpretation of the data and treatment landscape, however, slightly differs from theirs (Merz, M. & Gagelmann, N.
Open in Who Shared Issue with article?

Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy : A Systematic Review and Meta-Analysis

|
By Jaromir Tomasik, Mohammad Alhomoud, Samuel Yamshon, Edward Cliff, Gloria Iacoboni, Maximilian Merz, Marion Subklewe, Anat Gafter-Gvili, Saad Usmani, Gilles Salles, Miguel-Angel Perales, Grzegorz W. Basak, Kai Rejeski, Roni Shouval, Tobias Tix
| JAMA Oncology Verified
Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis Key Points Question What is the frequency of second primary malignant neoplasms (SPMs) in patients receiving T-cell–engaging bispecific antibodies for B-cell lymphoma or multiple myeloma?
Open in Who Shared Issue with article?

Does ciltacabtagene autoleucel have a future in multiple myeloma?

|
By Ghulam Rehman Mohyuddin, Edward Cliff, Rajshekhar Chakraborty
| Nature Verified
Ciltacabtagene autoleucel (cilta-cel) has transformed the outcomes of patients with relapsed or refractory multiple myeloma, yet its toxicity profile — spanning acute and delayed-onset neurotoxicity, secondary malignancies, immune effector-cell colitis, infections and prolonged cytopenias — has emerged slowly. As safer alternatives become available, the risk–benefit calculus for cilta-cel demands urgent reassessment, particularly in earlier lines of therapy.
Open in Who Shared Issue with article?
See all 22 licensed articles (31 Total)